Nachrichten zur Biogen Inc. Aktie

Biogen, Eisai to launch new Alzheimer therapy in Japan

…

Die Biogen-Aktie heute stark: Kurs legt deutlich zu (231,40 €)

Die Aktie von Biogen zählt am Montag zu den großen Gewinnern am Aktienmarkt. Der Titel steigt deutlich. Ein Preisanstieg auf…

Biogen: Die Markteinführung von Leqembi dürfte 2024 an Fahrt gewinnen - Upgrade! Aktienanalyse

St. Petersburg (www.aktiencheck.de) - Biogen-Aktienanalyse von Raymond James: Danielle Brill, Analystin von Raymond James, bewertet die Aktie von Biogen Inc. (ISIN:…

Biogen named a best idea for 2024 at Cowen

…

Biogen rises on new Best Idea at TD Cowen, upgrade at Raymond James By Investing.com

Biogen rises on new Best Idea at TD Cowen, upgrade at Raymond James…

Here are Thursdays biggest analyst calls: Nvidia, Rivian, Apple, AMD, Amazon, Biogen, DataDog, Bumble & more

Here are the biggest calls on Wall Street on Thursday.…

Biogen: Kurszielsenkung

San Francisco (www.aktiencheck.de) - Rating-Update: Wells Fargo Advisors stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP, NASDAQ-Symbol:…

Biogen: LAQEMBIs $10 Billion Potential

…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)

…

Biogen auf der Jahrestagung der Gesellschaft für Neuropädiatrie: Fortschritt bei seltenen Erkrankungen wie spinaler Muskelatrophie und Friedreich-Ataxie

Dortmund (ots) - Biogen Deutschland, ein führender Anbieter innovativer Therapien für neuromuskuläre und seltene Erkrankungen, ist vom 16. bis 18.…

Biogen cuts annual profit forecast on higher deal costs (Nov 8) By Reuters

Biogen cuts annual profit forecast on higher deal costs (Nov 8)…

Biogen: Kursziel erhöht

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten von RBC Capital Markets bewerten die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Biogen: Kursziel gekappt

Vancouver (www.aktiencheck.de) - Rating-Update: Die Analysten von Canaccord Genuity bewerten die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP,…

Biogen: Kursziel angehoben

San Francisco (www.aktiencheck.de) - Rating-Update: Mohit Bansal, Analyst von Wells Fargo Advisors, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen: BMO sieht weiterhin Potenzial - Aktienanalyse

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital Markets senken in einer aktuellen Aktienanalyse nach Veröffentlichung…

Biogen: Kursziel nach Zahlen gesenkt - Aktienanalyse

New York (www.aktiencheck.de) - Biogen-Aktienanalyse von J.P. Morgan Securities: Chris Schott, Analyst von J.P. Morgan Securities, senkt in einer aktuellen Aktienanalyse…

Biogen: Gemischte Q3-Ergebnisse - Aktienanalyse

London (www.aktiencheck.de) - Biogen-Aktienanalyse von Barclays: Carter Gould, Analyst von Barclays, senkt in einer aktuellen Aktienanalyse das Kursziel für die Aktie…

Biogens Uncertain Strategic Pivots Amidst MS Market Challenges

…

Biogen (BIIB) Q3 2023 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2023.…

Biogen lowers full-year earnings guidance, 3Q revenue beats expectations

Biogen Inc (NASDAQ:BIIB) revised its full-year earnings guidance downward due to acquisition-related costs following the company’s $7.3 billion bid for...…

Biogen swings to Q3 growth after Reata acquisition (update)

…

Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript

…

Leichter Wertverlust bei der Biogen-Aktie (215,1004 €)

Im Minus liegt derzeit die Biogen-Aktie . Der jüngste Kurs betrug 229,90 US-Dollar. Ein Preisabschlag in Höhe von 15,72 US-Dollar…

Biogen Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Biogen cuts annual profit forecast as higher costs persist By Reuters

Biogen cuts annual profit forecast as higher costs persist…

Biogen stock pops after earnings beat By Investing.com

Biogen stock pops after earnings beat…

: Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment

Company focuses on new products in Alzheimers, postpartum depression as multiple sclerosis product revenues decline…

Biogen cuts annual profit forecast on persistent higher costs

…

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact…

LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period

Stockholm, Sweden, November 7, 2023 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report…

Biogen Appoints Monish Patolawala to its Board of Directors

Biogen Appoints Monish Patolawala to its Board of Directors…

Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

Biogens (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis…

Earnings playbook: How to trade the biggest reports this week, including Disney

More than 45 S&P 500 names are slated to report this week, including Disney, Biogen and D.R. Horton.…

Eilt: Globaler Lizenzdeal voraus - Neuer 407% Biotech Aktientip nach 31.205% mit Amgen und 134.452% mit Biogen ($BIIB)

Calgary (www.aktiencheck.de, Anzeige) Einschätzung Strong OutperformerKurszieleKursziel 12M: 1,00 EUR Kurschance: 238% Kursziel 24M: 1,50 EUR Kurschance: 407%StammdatenISIN: CA98420Q2071 WKN: A3C9TS Ticker: ANU TSXV: XRTX.V NASDAQ: XRTXKursdatenKurs: 0,296 EUR 52W Hoch:…

Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy

…

SCLX: An Innovative and Growing Pain Management Company

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on…

More convenient form of breakthrough Alzheimers drug Leqembi shows promising results in study

Eisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the…

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake…

: Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.…

Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug

…

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data…

dpa-AFX ProFeed